9056 Federal Register / Vol. 87, No. 33 / Thursday, February 17, 2022 / Notices 

2 12 U.S.C. 225a. 3 12 U.S.C. 244. This authority permits the Board 

to collect personal information (e.g., bank account 

routing numbers) needed to disburse travel funds to 

CAC members. 

stable prices, and moderate long-term 

interest rates.’’ 2 Section 10 of the FRA 

authorizes the Board to ‘‘determine and 

prescribe the manner in which its 

obligations shall be incurred and its 

disbursements and expenses allowed 

and paid.’’ 3 Providing information 

collected as part of the Application is 

required to obtain a benefit. 

Generally, information provided on 

the Application may be kept 

confidential from the public under 

exemption 6 of the Freedom of 

Information Act (FOIA) to the extent 

that the disclosure of the information 

‘‘would constitute a clearly unwarranted 

invasion of personal privacy.’’ For 

example, the release of information such 

as the applicant’s address, home 

telephone number, or personal email 

address to the public would likely 

constitute a clearly unwarranted 

invasion of personal privacy and be kept 

confidential. However, the release of 

information such as the educational and 

professional qualifications of successful 

applicants would not likely constitute a 

clearly unwarranted invasion of 

personal privacy and may be disclosed 

under the FOIA. In addition, once a 

person becomes a member of the CAC, 

their name, and the name and location 

of the organization where they are 

employed, would generally be listed on 

the Board’s public website. 

Current actions: On October 5, 2021, 

the Board published a notice in the 

Federal Register (86 FR 54977) 

requesting public comment for 60 days 

on the extension, without revision, of 

the Application Form for Membership 

on the Community Advisory Committee 

Council. The comment period for this 

notice expired on December 6, 2021. 

The Board did not receive any 

comments. 

Board of Governors of the Federal Reserve 

System, February 14, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–03471 Filed 2–16–22; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; FFY 2022 CCDF Discretionary 

Funds Reallotment (0970–0510) 

AGENCY: Office of Child Care, 

Administration for Children and 

Families, HHS. 

ACTION: Request for public comment. 

SUMMARY: The Administration for 

Children and Families (ACF), Office of 

Child Care (OCC) plans to submit a 

generic information collection (GenIC) 

request under the following umbrella 

generic: Generic Clearance for Financial 

Reports used for ACF Mandatory Grant 

Programs (0970–0510). This request 

includes a draft announcement with 

instructions to be completed by Child 

Care and Development Fund (CCDF) 

grant recipients that will be unable to 

obligate funds that will reach the end of 

their obligation period on September 30, 

2022. 

DATES: Comments due within 14 days of 

publication. In compliance with the 

requirements of the Paperwork 

Reduction Act of 1995, ACF is soliciting 

public comment on the specific aspects 

of the information collection described 

above and below. 

ADDRESSES: Copies of the proposed 

collection of information can be 

obtained and comments may be 

submitted by emailing infocollection@

acf.hhs.gov. All requests should be 

identified by the title of the information 

collection. 

SUPPLEMENTARY INFORMATION: 

Description: CCDF regulations 

authorize HHS to reallot funds to other 

state and tribal lead agencies that cannot 

be obligated by states or tribes by the 

obligation deadline. Pursuant to the 

CCDF Rule (45 CFR 98.64), each year, 

the state and tribal lead agency must 

report to the Secretary the dollar 

amount from the previous year’s grant 

that it will be unable to obligate by the 

end of the obligation period. Such 

reports must be postmarked or emailed 

by April 1. If the Secretary does not 

receive a report, any funds that are not 

obligated by the obligation deadline will 

revert to the Federal Government. 

For the purposes of this data 

collection, ‘‘state’’ refers to the 50 states, 

the District of Columbia, and the 

Commonwealth of Puerto Rico. 

The Generic Clearance for Financial 

Reports used for ACF Mandatory Grant 

Programs allows ACF programs to assist 

in the computation of the grant awards 

issued to each program’s grantees. For 

more information about the umbrella 

generic, see: https://www.reginfo.gov/ 

public/do/PRAViewDocument?ref_nbr=

202108-0970-002. 

This specific GenIC will be issued as 

a Program Instruction and an email 

announcement on the OCC listserv. 

State and tribal lead agencies that will 

be unable to obligate their funds by 

September 30, 2022, must inform ACF 

by April 1, 2022. Lead Agencies should 

submit a letter by mail or email signed 

by an official authorized to make 

financial decisions (e.g., Tribal Chair, 

Agency Director) to their OCC Regional 

Program Manager and ACF Regional 

Grants Management Specialist. The 

letter or email should report the amount 

of funds for each of the following 

funding streams that the Lead Agency 

will be unable to obligate: Grant year 

2021 CCDF discretionary funds, and 

CCDF supplemental funds awarded 

under the Additional Supplemental 

Appropriations for Disaster Relief Act, 

2019 (Pub. L. 116–20); the Coronavirus 

Aid, Relief, and Economic Security Act 

(Pub. L. 116–136); the Coronavirus 

Response and Relief Supplemental 

Appropriations Act (Pub. L. 116–260); 

and the American Rescue Plan Act child 

care stabilization funds (Pub. L. 117–2). 

ACF will de-obligate funds that are 

reported and re-allot those funds to state 

and tribal lead agencies that request the 

funds. 

Respondents: Respondents will be 

state and tribal officials authorized to 

report on behalf of the CCDF program, 

which will likely be CCDF program 

administrators. 

ANNUAL BURDEN ESTIMATES

Title of information collection Number of 

respondents 

Annual 

frequency of 

responses 

Hourly 

burden per 

response 

Annual hourly 

burden 

FFY 2022 CCDF Discretionary Funds for Reallotment ................................... 317 1 1 317 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 33 / Thursday, February 17, 2022 / Notices 9057 

Estimated Total Annual Burden 

Hours: 317. 

Comments: The Department 

specifically requests comments on (a) 

whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Consideration will be given 

to comments and suggestions submitted 

within 14 days of this publication. 

Authority: 45 CFR 98.64. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–03462 Filed 2–16–22; 8:45 am] 

BILLING CODE 4184–55–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2019–N–0895] 

Issuance of Priority Review Voucher; 

Material Threat Medical 

Countermeasure Product 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

issuance of a priority review voucher to 

the sponsor of a material threat medical 

countermeasure (MCM) product 

application. The Federal Food, Drug, 

and Cosmetic Act (FD&C Act), as 

amended by the 21st Century Cures Act 

(Cures Act), authorizes FDA to award 

priority review vouchers to sponsors of 

approved material threat MCM product 

applications that meet certain criteria. 

FDA is required to publish notice of the 

award of the priority review voucher. 

FDA has determined that SPIKEVAX

(COVID–19 Vaccine, mRNA), meets the 

criteria for a material threat priority 

review voucher, which has been issued 

to ModernaTX, Inc., the holder of the 

biologics license application. 

FOR FURTHER INFORMATION CONTACT: 

Myrna Hanna, Center for Biologics 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 71, Rm. 7301, 

Silver Spring, MD 20993–0002, 240– 

402–7911. 

SUPPLEMENTARY INFORMATION: FDA is 

announcing the issuance of a material 

threat MCM priority review voucher to 

the sponsor of an approved material 

threat MCM product application. Under 

section 565A of the FD&C Act (21 U.S.C. 

360bbb–4a), which was added by the 

Cures Act (Pub. L. 114–255), FDA will 

award priority review vouchers to 

sponsors of approved material threat 

MCM product applications that meet 

certain criteria upon approval of those 

applications. FDA has determined that 

SPIKEVAX (COVID–19 Vaccine, 

mRNA), meets the criteria for a material 

threat MCM priority review voucher. 

SPIKEVAX is indicated for active 

immunization to prevent coronavirus 

disease 2019 (COVID–19) caused by 

severe acute respiratory syndrome 

coronavirus 2 (SARS–CoV–2) in 

individuals 18 years of age and older. 

For further information about the 

material threat MCM Priority Review 

Voucher Program and for a link to the 

full text of section 565A of the FD&C 

Act, go to https://www.fda.gov/ 

emergency-preparedness-and-response/ 

mcm-legal-regulatory-and-policyframework/mcm-relatedcounterterrorism-legislation. For further 

information about SPIKEVAX, (COVID– 

19 Vaccine, mRNA), go to the Center for 

Biologics Evaluation and Research 

Approved Vaccine Products website at 

https://www.fda.gov/vaccines-bloodbiologics/vaccines/approved-vaccineproducts. 

Dated: February 11, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–03420 Filed 2–16–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2021–N–0386] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Class II Special 

Controls for Human Immunodeficiency 

Virus Serological Diagnostic and 

Supplemental Tests and Human 

Immunodeficiency Virus Nucleic Acid 

Diagnostic and Supplemental Tests 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing that a proposed collection 

of information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Submit written comments 

(including recommendations) on the 

collection of information by March 21, 

2022. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be submitted to https://

www.reginfo.gov/public/do/PRAMain. 

Find this particular information 

collection by selecting ‘‘Currently under 

Review—Open for Public Comments’’ or 

by using the search function. The OMB 

control number for this information 

collection is 0910–0437. Also include 

the FDA docket number found in 

brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Domini Bean, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–5733, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Medical Device Reporting—21 CFR Part 

803 

OMB Control Number 0910–0437— 

Revision 

In the Federal Register of February 

21, 2020 (85 FR 10110), we published a 

proposed order to reclassify certain 

human immunodeficiency virus (HIV) 

serological diagnostic and supplemental 

tests and HIV nucleic acid (NAT) 

diagnostic and supplemental tests from 

class III (premarket approval) into class 

II (special controls) (the proposed 

order). In the proposed order, FDA 

proposed special controls that the 

Agency believes are necessary to 

provide a reasonable assurance of safety 

and effectiveness for these devices. The 

proposed special controls would require 

the submission of a log of all complaints 

annually for a period of 5 years 

following FDA clearance of a traditional 

premarket notification (510(k)) 

submission for a device within the 

scope of the proposed order. 

Currently, manufacturers of HIV 

serological diagnostic and supplemental 

tests and HIV NAT diagnostic and 

supplemental tests are subject to FDA 


lotter on DSK11XQN23PROD with NOTICES1